Sorana Morrissy
Assistant Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
Xenograft models, in which human tumors are implanted into mouse hosts, offer a unique platform to study tumor-microenvironment (TME) interactions. Ligand-receptor (LR) interactions are central to intercellular communication in this context, but most inference tools rely on single-species databases and assume conserved function across orthologues. To test whether this assumption holds given sequence and structural divergence, we developed XenoSignal, a computational framework that integrates AlphaFold3 structural predictions to assess the plausibility of intraspecies and interspecies LR interactions. The pipeline predicts whether human-mouse orthologues retain or lose their functional interaction, enabling construction of a high-confidence cross-species LR resource. XenoSignal facilitates the interpretation of tumor-TME crosstalk in xenografts and prioritizes LR pairs for experimental validation. This resource enhances our ability to dissect interspecies signaling, uncover mechanisms of immune evasion, and identify candidate therapeutic targets in translational cancer models.
Year:
2025
Engineered virus-like particles (eVLPs) enable transgene-free ribonucleoprotein delivery for genome editing applications, yet optimized delivery strategies for high-throughput applications remain unexplored. Prime editing enables precise genomic modifications but suffers from limited efficiency that constrains its widespread adoption. Here, we present PRIME-VLP (Progressive Repeated Infections for Maximized Editing via Virus-Like Particles), a delivery strategy that enhances prime editing efficiency for both targeted genome engineering and high-throughput prime editing screening. PRIME-VLP leverages the temporal dynamics of eVLP-mediated editing through multiple sequential transductions with sub-saturating eVLP doses delivered at optimal intervals. This approach achieves 1.5 to 2.8-fold improvements in editing efficiency across diverse genomic targets and cell types. PRIME-VLP maintains high specificity without increasing off-target effects, compromising cellular viability or causing transcriptional perturbations. By decoupling pegRNA and editor delivery through pegRNA-free eVLPs, PRIME-VLP enables pooled prime editing screens, circumventing transgene silencing limitations of conventional lentiviral-based screens. Using a 6,000-pegRNA library targeting TP53 , PRIME-VLP achieved 2.8-fold higher editing efficiency and improved reproducibility compared to conventional lentiviral delivery. An eVLP-based screen identified functional TP53 loss-of-function variants that confer resistance to MDM2 inhibition by Nutlin-3. This work expands the versatility of eVLPs beyond their current in vivo therapeutic applications, demonstrating their promise for high-throughput functional genomics by overcoming the delivery limitations of lentiviral systems.
Year:
2025
Spatial transcriptomics technologies advance our understanding of complex biology by directly profiling cellular organization within tissues. However, accurate deconvolution of cell types and functional states remains challenging as most current computational methods either rely on high-quality matched single-cell reference profiles (often lacking for many tissues or disease states), struggle across spatial resolutions and under variable sequencing depths, and face scalability bottlenecks in large datasets. To address these challenges, we developed an optimal transport-based non-negative matrix factorization method (spOT-NMF) that leverages the Wasserstein distance to disentangle mixed gene expression signals in a reference-free manner. Benchmarking against well-established unsupervised deconvolution approaches demonstrates top performance of spOT-NMF in simulated and real spatial transcriptomics data spanning sub-cellular to multi-cellular resolutions, across multiple platforms, in two-species admixture scenarios such as xenografts, and in human cancer. We provide spOT-NMF as a freely available package for spatial data analysis, supporting GPU acceleration for large-scale analyses.
Year:
2025
CAR T therapy for solid tumors is limited by a lack of safe and uniformly expressed cell-surface targets. Here, we identify the MiT fusion-driven protein GPNMB as being highly, homogeneously, and stably expressed in primary and relapsed translocation-positive alveolar soft part sarcoma (ASPS) and renal cell carcinoma (tRCC). We developed a GPNMB-targeting CAR T therapy called GCAR1 that shows activity against patient-matched cells, organoids and xenograft models. First-in-human treatment of a patient with metastatic ASPS was well tolerated and generated stable disease until 6 months, with many non-target lesions resolving post-treatment. A polyclonal population of GCAR1 cells expanded in blood and were detectable until 6 months. Spatial transcriptomics revealed multiple immunosuppressive niches in proximity to T cells infiltrating a treatment-resistant lesion, and PDL1 blockade showed synergy with GCAR1 in a xenograft model. Our data provide clinical evidence for treating solid tumors with CAR T cells targeting a surface protein driven by an oncogenic gene fusion.
Year:
2025
Chimeric antigen receptor (CAR) T-cell therapy has remarkably succeeded in treating lymphoblastic leukemia. However, its success in acute myeloid leukemia (AML) remains elusive because of the risk of on-target off-tumor toxicity to hematopoietic stem/progenitor cells (HSPC) and insufficient T-cell persistence and longevity. Using a SynNotch circuit, we generated a high-precision “IF-THEN” gated logical circuit against the combination of CD33 and CD123 AML antigens and demonstrated antitumor efficacy against AML cell lines and patient-derived xenografts. Unlike constitutively expressed CD123 CAR-T cells, those expressed through the CD33 SynNotch circuit could preserve HSPCs and lower the risk of on-target off-tumor hematopoietic toxicity. These gated CAR-T cells exhibited lower expression of exhaustion markers (PD-1, TIM-3, LAG-3, and CD39), higher frequency of memory T cells (CD62L + CD45RA + ), and enhanced expansion. Although targeting AML, the moderated circuit CAR signal also helped mitigate cytokine release syndrome, potentially addressing one of the ongoing challenges in CAR-T immunotherapy. Significance: Our study demonstrates the use of “IF-THEN” SynNotch-gated CAR-T cells targeting CD33 and CD123 in AML reduces off-tumor toxicity. This strategy enhances T-cell phenotype, improves expansion, preserves HSPCs, and mitigates cytokine release syndrome—addressing critical limitations of existing AML CAR-T therapies.
Year:
2025
Advances in molecular profiling have facilitated generation of large multi-modal datasets that can potentially reveal critical axes of biological variation underlying complex diseases. Distilling biological meaning, however, requires computational strategies that can perform mosaic integration across diverse cohorts and datatypes. Here, we present mosaicMPI, a framework for discovery of low to high-resolution molecular programs representing both cell types and states, and integration within and across datasets into a network representing biological themes. Using existing datasets in glioblastoma, we demonstrate that this approach robustly integrates single cell and bulk programs across multiple platforms. Clinical and molecular annotations from cohorts are statistically propagated onto this network of programs, yielding a richly characterized landscape of biological themes. This enables deep understanding of individual tumor samples, systematic exploration of relationships between modalities, and generation of a reference map onto which new datasets can rapidly be mapped. mosaicMPI is available at https://github.com/MorrissyLab/mosaicMPI.
Year:
2024
Collaborators (5)
Michael A. Pulsipher
University of Utah Health Huntsman Cancer Institute
Alexandra Kovach
Director, Hematopathology; Associate Professor, Keck School of Medicine of University of Southern California
Children's Hospital of Los Angeles
Yong-Mi Kim
Professor of Pediatrics and Pathology (with Tenure)
University of Southern California Keck School of Medicine
Shahab Asgharzadeh
University of Southern California
chintan parekh
Assistant Professor
University of Southern California
Make your next move.
Prepare your application
Review drafts before you send them.